3 recruiting, 1 not yet recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow IBI3003: new trials by email Literature Review of IBI3003 trials Research Report on IBI3003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma IBI3003 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fortvita Biologics (USA)Inc. | 360 | 2026-09-30 | 2026-09-25 |
| A Open-Label Phase in Participants With Multiple Myeloma Dexamethasone, IBI3003, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 120 | 2026-08-15 | 2026-08-14 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma IBI3003 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 116 | 2024-07-29 | 2024-12-13 |
Multiple Myeloma (4) · Recurrence (1)
Innovent Biologics (Suzhou) Co. Ltd. (3) · Fortvita Biologics (USA)Inc. (1)
China (3) · Australia (1) · United States (1)